Mucositis

Summary

Mucositis (MONDO:0020579) is a disease (an umbrella term covering 6 Mondo subtypes) and 107 clinical trials. Top therapeutic interventions include palifermin, amifostine, and chlorhexidine gluconate. A subtype of inflammatory disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 6 Mondo subtypes
• Clinical trials: 107

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mucositis
Mondo ID	MONDO:0020579
MeSH	D052016
NCIT	C115965
UMLS	C0333355
MedGen	87165
Is cancer (heuristic)	no

Also known as: inflammation of mucosa · mucosa inflammation · mucositis

Disease family

This is a subtype of inflammatory disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › inflammatory disease › mucositis

Related subtypes (93): chorioamnionitis, pyometritis, uvulitis, mastoiditis, pelvic inflammatory disease, tonsillitis, nasopharyngitis, petrositis, nephritis, esophagitis, geniculate ganglionitis, epicondylitis, labyrinthitis, lymphadenitis, cheilitis, neuritis, vaginitis, hepatitis, pharyngitis, hidradenitis, gastroenteritis, dermatitis, bursitis, laryngitis, keratitis, endocervicitis, conjunctivitis, spondylitis, thyroiditis, diverticulitis, neuronitis, mediastinitis, epididymitis, blepharitis, cholangitis, dacryoadenitis, fasciitis, chronic inflammation of lacrimal passage, dacryocystitis, periostitis, gastritis, pancreatitis, periodontitis, encephalomyelitis, placental villitis, prostatitis, urethritis, otitis media, perianal Crohn disease, proctitis, arthritic joint disease, oral tuberculosis, parotitis, pericarditis, sinusitis, cystitis, panniculitis, balanitis, chronic inflammatory demyelinating polyradiculoneuropathy, glossitis, mastitis, oophoritis, orchitis, perinephritis, pulpitis, rheumatic heart disease, vulvitis, thromboangiitis obliterans, STING-associated vasculopathy with onset in infancy, endophthalmitis, chronic granulomatous disease, IgG4-related pachymeningitis, vasculitis, chronic pneumonitis of infancy, uveitis, amnionitis, diaphragmitis, gonococcal cervicitis, posthitis, myositis disease, omphalitis, ear infection, radiculitis, tracheobronchitis, ureteritis, enthesitis, inflammation of heart layer, serositis, pneumonitis, immune reconstitution inflammatory syndrome, multiple evanescent white dot syndrome, isolated anogenital granulomatosis, myelin oligodendrocyte glycoprotein antibody-associated disease

Subtypes (6): gastrointestinal mucositis, endometritis, rhinitis, stomatitis, epiglottitis, tracheitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 7 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Palifermin	Approved (phase 4)
Acetylcysteine	Phase 3 (in late-stage trials)
Cisplatin	Phase 3 (in late-stage trials)
Glutamine	Phase 3 (in late-stage trials)
Hydromorphone	Phase 3 (in late-stage trials)
Ketamine	Phase 3 (in late-stage trials)
Sodium Fluoride	Phase 3 (in late-stage trials)
Triclosan	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Acetaminophen, Bupivacaine, Folic Acid, Gabapentin, Lipoic Acid, Alpha, Morphine, Simvastatin, Zinc Sulfate.

Clinical trials & evidence

Clinical trials

Clinical trials: 107.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	45
PHASE2	26
PHASE3	15
PHASE1/PHASE2	6
PHASE1	6
PHASE4	5
PHASE2/PHASE3	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00357942	PHASE4	COMPLETED	Topical Morphine for Stomatitis-related Pain Induced by Chemotherapy
NCT00449592	PHASE4	COMPLETED	Oral Zinc Therapy for the Prevention of Mucositis
NCT01707641	PHASE4	UNKNOWN	Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer
NCT03047291	PHASE4	COMPLETED	Effect of Probiotic Lactobacillus Reuteri in the Treatment of Mucositis and Periimplantitis
NCT05211622	PHASE4	UNKNOWN	OZOCLO_MUCOSITIS: a New Protocol for Prevention of Oral Mucositis
NCT00101582	PHASE3	COMPLETED	Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
NCT00224692	PHASE3	TERMINATED	Analgesic Effect in Children of Low-Dose Ketamine for Mucositis Treated by Patient-Controlled Analgesia With Morphine
NCT00360971	PHASE3	TERMINATED	Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer
NCT00474110	PHASE3	WITHDRAWN	Ketamine and Hydromorphone for Patient Controlled Pain Relief in Children’s Mucositis
NCT00814359	PHASE3	COMPLETED	Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis
NCT00956254	PHASE3	COMPLETED	Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis
NCT01015183	PHASE2/PHASE3	COMPLETED	Prevention Chemotherapy Induced Mucositis by Zinc Sulfate
NCT01072201	PHASE3	COMPLETED	To Access the Effects of Mucositis in Adults With Dental Implants
NCT01156142	PHASE3	COMPLETED	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
NCT01305200	PHASE3	COMPLETED	Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
NCT02085694	PHASE2/PHASE3	UNKNOWN	Lactobacillus Brevis CD2 Preventing Oral Mucositis
NCT02282839	PHASE3	UNKNOWN	Oral Glutamine and Mucositis of Head and Neck Cancer Patients Undergoing Radiation
NCT02313792	PHASE3	UNKNOWN	Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation
NCT02480114	PHASE3	COMPLETED	Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy
NCT02506231	PHASE2/PHASE3	UNKNOWN	The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome
NCT04756622	PHASE3	UNKNOWN	N-acetyl Cysteine for the Prevention of Oral Mucositis After Autologous Hematopoietic Cell Transplantation.
NCT04988971	PHASE3	UNKNOWN	The Efficacy and Safety of a Compound Glutamine Capsule in the Prevention of Chemotherapy-induced Mucositis
NCT05092113	PHASE3	UNKNOWN	The Efficacy and Safety of a Compound Glutamine Capsule in the Primary Prevention of Chemotherapy-induced Mucositis
NCT03480971	PHASE2	RECRUITING	Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
NCT03581773	PHASE2	RECRUITING	Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy
NCT00095927	PHASE2	COMPLETED	Randomized Amifostine For SCCHN
NCT00163280	PHASE2	COMPLETED	Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis
NCT00503776	PHASE2	TERMINATED	Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
NCT00533078	PHASE2	COMPLETED	Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies
NCT00626639	PHASE1/PHASE2	COMPLETED	A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy
NCT00727831	PHASE1/PHASE2	COMPLETED	Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
NCT01087476	PHASE2	UNKNOWN	Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate
NCT01432873	PHASE1/PHASE2	UNKNOWN	Oral Selenium Therapy for the Prevention of Mucositis
NCT01566448	PHASE2	COMPLETED	Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash
NCT01653327	PHASE2	COMPLETED	Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head & Neck Cancer
NCT01674374	PHASE2	WITHDRAWN	Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy
NCT01682031	PHASE2	TERMINATED	Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy
NCT01737307	PHASE2	COMPLETED	Effect of Fluoride Varnish and CPP-ACP on Oral and Salivary Symptoms During Chemotherapy
NCT01762514	PHASE2	UNKNOWN	A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens
NCT01974596	PHASE2	COMPLETED	Use of Probiotics in Oral Health of Patients With Dental Implants

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PALIFERMIN	4	6
AMIFOSTINE	4	2
CHLORHEXIDINE GLUCONATE	4	2
GLUTAMINE	4	2
DOXEPIN HYDROCHLORIDE	4	1
DOXYCYCLINE HYCLATE	4	1
FISH OIL TRIGLYCERIDES	4	1
FOLIC ACID	4	1
GLUCARPIDASE	4	1
HYDROCODONE	4	1
HYDROMORPHONE	4	1
MORPHINE	4	1
NELARABINE	4	1
PHENYLEPHRINE	4	1
SELENOMETHIONINE	4	1
TRICLOSAN	4	1
ZINC SULFATE	4	1
FLUORIDE ION	3	2
BICARBONATE	3	1
CURCUMIN	3	1
SELENIUM	3	1
XYLITOL	3	1
ZINC ION	3	1
TK-112690	2	3
BRILACIDIN	2	1
ENTOLIMOD	2	1
LYSINE	2	1
TEMPOL	2	1
CHEMBL4589226	0	2
CHEMBL1628	0	2